Grufity logoGrufity logo

Fate Therapeutics Inc Stock Research

FATE

5.48USD+0.09(+1.67%)Market Closed

Market Summary

USD5.48+0.09
Market Closed
1.67%

FATE Alerts

FATE Stock Price

FATE RSI Chart

FATE Valuation

Market Cap

533.2M

Price/Earnings (Trailing)

-1.89

Price/Sales (Trailing)

5.54

Price/Free Cashflow

-1.88

FATE Price/Sales (Trailing)

FATE Profitability

Return on Equity

-58.21%

Return on Assets

-39.93%

Free Cashflow Yield

-53.22%

FATE Fundamentals

FATE Revenue

Revenue (TTM)

96.3M

Revenue Y/Y

159.86%

Revenue Q/Q

196.08%

FATE Earnings

Earnings (TTM)

-281.7M

Earnings Y/Y

17.86%

Earnings Q/Q

32.55%

Price Action

52 Week Range

4.0243.12
(Low)(High)

Last 7 days

-1.4%

Last 30 days

-5.3%

Last 90 days

-46.3%

Trailing 12 Months

-85.6%

FATE Financial Health

Current Ratio

4.4

FATE Investor Care

Shares Dilution (1Y)

1.64%

Diluted EPS (TTM)

-2.91

Peers (Alternatives to Fate Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
126.4B
26.3B
1.33% 2.31%
19.3
4.8
1.32% 11.18%
99.2B
27.3B
-0.40% 40.80%
21.61
3.64
-0.09% -26.23%
57.1B
19.3B
6.53% -10.59%
6.83
2.96
4.29% -31.47%
39.0B
10.2B
-0.01% 27.97%
12.8
3.83
-7.36% 95.80%
MID-CAP
9.4B
1.5B
-5.27% 3.55%
60.62
6.29
31.34% 72.43%
3.2B
108.5M
-10.19% -29.91%
-9.71
29.17
122.90% -12.19%
2.2B
60.9M
-21.53% -47.37%
-7.53
35.73
17.51% 22.00%
2.2B
107.9M
22.92% 38.22%
-4.45
19.98
54.84% 17.36%
SMALL-CAP
1.3B
112.0M
-3.60% -50.92%
-4.82
11.49
-70.76% -603.77%
1.1B
7.0M
-2.83% 20.33%
-6.95
155.42
131.81% -45.39%
533.2M
96.3M
-5.35% -85.58%
-1.89
5.54
72.44% -32.79%
524.0M
2.0B
-30.95% -91.78%
-0.8
0.26
72.89% 62.27%
290.2M
111.3M
-34.46% -69.74%
-1.51
2.61
0.54% -7.86%
102.0M
107.0K
-5.82% -84.77%
-0.95
953.19
-88.00% -52.91%
30.1M
-
102.50% -80.56%
-0.37
3.21
0.51% -185.61%

Financials for Fate Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue39.5%96,300,00069,013,00068,257,00063,120,00055,846,000
Operating Expenses5.8%404,686,000382,362,000349,838,000308,371,000272,840,000
  S&GA Expenses5.8%84,232,00079,584,00073,747,00065,564,00057,321,000
  R&D Expenses5.8%320,454,000302,778,000276,091,000242,807,000215,519,000
Interest Expenses-0.00----
Net Income4.2%-281,721,000-293,979,000-253,724,000-232,752,000-212,151,000
Net Income Margin31.3%-2.93-4.26-3.72-3.69-
Free Cahsflow2.3%-283,774,000-290,370,000-274,757,000-257,194,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-5.8%706749807858921
  Current Assets-6.2%502535599599633
    Cash Equivalents-25.3%61.0082.0055.0065.00134
  Net PPE0.8%11010910398.0092.00
  Current Liabilities9.7%11410492.0078.0081.00
Shareholder's Equity-6.6%484518580633679
  Retained Earnings-5.7%-1,050-994-910-834-769
  Additional Paid-In Capital1.4%1,5361,5161,4951,4711,449
Shares Outstanding0.2%97.0097.0097.0097.0096.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-2.1%-248-243-221-200-162
  Share Based Compensation6.5%79.0074.0068.0061.0054.00
Cashflow From Investing-9.8%167185182141-324
Cashflow From Financing-17.1%9.0011.0018.0018.00453

Risks for FATE

What is the probability of a big loss on FATE?

100%


Probability that Fate Therapeutics stock will be more than 20% underwater in next one year

98.1%


Probability that Fate Therapeutics stock will be more than 30% underwater in next one year.

32.7%


Probability that Fate Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FATE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Fate Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for FATE

Cumulative Returns on FATE

16.8%


7-Year Cumulative Returns

-10.5%


5-Year Cumulative Returns

-37.2%


3-Year Cumulative Returns

What are the long-term rolling returns for FATE?

FIve years rolling returns for Fate Therapeutics.

Annualized Returns

Which funds bought or sold FATE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
unchanged
-
-542,130
444,000
-%
2023-03-17
American Portfolios Advisors
added
15.03
2,590
66,894
-%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
-4,247
3,753
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-22.54
-14,316,600
7,666,400
0.01%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-
-
-%
2023-03-03
TIAA, FSB
unchanged
-
-216,497
177,503
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-393,513
322,487
-%
2023-02-24
NATIXIS
new
-
28,968
28,968
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-40,000
-
-%
2023-02-17
Coppell Advisory Solutions Corp.
new
-
42,277
42,277
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying FATE calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own FATE
No. of Funds

Fate Therapeutics News

Benzinga

15 Analysts Have This to Say About Fate Therapeutics - Fate ....

Benzinga,
8 hours ago

Business Wire

Schedule 13G FIlings of Fate Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 22, 2023
millennium management llc
1.7%
1,696,431
SC 13G
Mar 10, 2023
vanguard group inc
10.12%
9,936,042
SC 13G/A
Feb 13, 2023
capital world investors
5.8%
5,591,517
SC 13G
Feb 09, 2023
vanguard group inc
8.20%
7,972,551
SC 13G/A
Feb 03, 2023
state street corp
6.11%
5,935,459
SC 13G
Jan 06, 2023
blackrock inc.
10.0%
9,725,895
SC 13G/A
Feb 09, 2022
ark investment management llc
10.80%
10,312,167
SC 13G/A
Feb 03, 2022
blackrock inc.
7.4%
7,060,552
SC 13G/A
Oct 12, 2021
fmr llc
-
0
SC 13G/A
Sep 10, 2021
ark investment management llc
11.34%
10,790,423
SC 13G

FATE Fair Value

Fate Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Fate Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.22

-95.99%

0.47

-91.42%

1.42

-74.09%

3.03

-44.71%

6.27

14.42%
Current Inflation

0.20

-96.35%

0.42

-92.34%

1.25

-77.19%

2.64

-51.82%

5.39

-1.64%
Very High Inflation

0.17

-96.90%

0.37

-93.25%

1.05

-80.84%

2.17

-60.40%

4.39

-19.89%

Historical Fate Therapeutics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Fate Therapeutics

View All Filings
Date Filed Form Type Document
Mar 22, 2023
SC 13G
Major Ownership Report
Mar 10, 2023
SC 13G/A
Major Ownership Report
Feb 28, 2023
10-K
Annual Report
Feb 28, 2023
8-K
Current Report
Feb 13, 2023
SC 13G
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 07, 2023
4
Insider Trading
Feb 07, 2023
4
Insider Trading
Feb 07, 2023
4
Insider Trading
Feb 07, 2023
4
Insider Trading

Latest Insider Trading transactions for FATE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-19
MENDLEIN JOHN
acquired
38,991
1.37
28,461
-
2023-01-13
MENDLEIN JOHN
bought
198,906
5.43
36,631
-
2023-01-12
Valamehr Bahram
acquired
579
1.37
423
chief r&d officer
2023-01-11
MENDLEIN JOHN
bought
499,232
5.67
88,048
-
2023-01-10
TAHL CINDY
sold
-60,537
5.24
-11,553
general counsel and secretary
2023-01-10
Wolchko J Scott
sold
-240,553
5.24
-45,907
president and ceo
2023-01-10
Plavsic Mark
sold
-17,910
5.24
-3,418
chief technical officer
2023-01-10
Dulac Edward J III
sold
-38,414
5.24
-7,331
chief financial officer
2023-01-10
Chu Yu-Waye
sold
-41,003
5.24
-7,825
chief medical officer
2023-01-10
Valamehr Bahram
sold
-57,205
5.24
-10,917
chief r&d officer

1–10 of 50

J. Scott Wolchko
450
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Collaboration revenue$ 96,300$ 55,846$ 31,434
Type of Revenue [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:   
Research and development$ 320,454$ 215,519$ 125,623
General and administrative84,23257,32133,896
Total operating expenses404,686272,840159,519
Loss from operations(308,386)(216,994)(128,085)
Other income (expense):   
Interest income5,8421,3092,400
Change in fair value of stock price appreciation milestones20,3073,534(47,702)
Other income51600
Total other income (expense), net26,6654,843(45,302)
Net loss(281,721)(212,151)(173,387)
Other comprehensive loss:   
Unrealized (loss) gain on available-for-sale securities, net(1,092)(832)48
Comprehensive loss$ (282,813)$ (212,983)$ (173,339)
Earnings Per Share, Basic$ (2.91)$ (2.24)$ (2.10)
Earnings Per Share Diluted$ (2.91)$ (2.24)$ (2.10)
Weighted Average Number of Shares Outstanding, Basic96,826,05894,747,31182,385,319
Weighted Average Number of Shares Outstanding, Diluted96,826,05894,747,31182,385,319

FATE Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 61,333$ 133,583
Accounts receivable38,4808,676
Short-term investments374,894482,327
Prepaid expenses and other current assets27,3678,826
Total current assets502,074633,412
Long-term investments4,942100,664
Property and equipment, net110,02091,529
Operating lease right-of-use assets66,06970,720
Restricted cash15,22715,227
Collaboration contract assets7,1969,870
Other assets3333
Total assets705,561921,455
Current liabilities:  
Accounts payable8,2658,612
Accrued expenses53,93242,412
CIRM award liability, current portion4,0003,200
Deferred revenue, current portion42,22621,483
Operating lease liabilities, current portion5,6285,577
Total current liabilities114,05181,284
Deferred revenue, net of current portion027,124
CIRM award liability, net of current portion0800
Operating lease liabilities, net of current portion103,710109,241
Stock price appreciation milestones, net of current portion3,86124,168
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; authorized shares--5,000,000 at December 31, 2022 and December 31, 2021; Class A Convertible Preferred shares issued and outstanding--2,794,549 at December 31, 2022 and December 31, 202133
Common stock, $0.001 par value; authorized shares--250,000,000 at December 31, 2022 and December 31, 2021; issued and outstanding --97,294,917 at December 31, 2022 and 95,726,962 at December 31, 20219796
Additional paid-in capital1,536,4971,448,584
Accumulated other comprehensive (loss) gain(1,854)(762)
Accumulated deficit(1,050,804)(769,083)
Total stockholders’ equity483,939678,838
Total liabilities and stockholders’ equity$ 705,561$ 921,455